annb0t
Top 20
Incannex Healthcare Limited (NASDAQ: IXHL) announced interim review results from its ongoing Phase 2 clinical trial of the psilocybin-assisted psychotherapy program for Generalised Anxiety Disorder (GAD), known as PsiGAD. IHL has reviewed the interim data from the first 29 participants to complete the treatment protocol and completed a conditional power analysis using the interim data to model and project total study data. The company found a high probability (greater than 85% - alpha error 0.05...
>>> Read more: Why Incannex Healthcare Shares Are Gaining Today
>>> Read more: Why Incannex Healthcare Shares Are Gaining Today
